Bristol-myers Squibb Compnay

Pfizer Corporation

Medarex Inc.

E. R. Squibb Sons, Inc.

Kristopher Toy

Haichun Huang

Brigitte Devaux

Peter Brams

Lan Yang

Arvind Rajpal

Heidi N Leblanc

Chetana Rao-Naik

David B Passmore

Ronald P Gladue

Barrett Richard Thiele

Yanli Wu

Wei Liao

Yi Wu

Rory Francis Finn

Jing Min

Timothy J Paradis

Jonathan Alexander Terrett

Sarah Lee Pogue

Mark Yamanaka

Bingliang Chen

Dawn M Tanamachi

Tim Sproul

Jun Zhang

Madhav Narasimha Devalaraja

David J King

Steven Lee Bender

Alison Witte

Haibin Chen

Richard Theolis

Kyra D Zens

Michael Aidan North

Gerald Fries Casperson

Dana Dan Hu-Lowe

Gang Li

Xin Jiang

Jianying Wang

Asna Masood

Grant Wickman

Sarah R Reed

Alan J Korman

Edward L Halk

Kent B Thudium

Changyu Wang

Tim W Sproul

Ronald Paul Gladue

Timothy Joseph Paradis

Wei Laio

Sara R Dwiggins

David John King

The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

Binding molecules to the human OX40 receptor

The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.

Human antibodies that bind CD22 and uses thereof

Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.

Antibodies to IL-6 and their uses

The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure.

Human antibodies that bind mesothelin, and uses thereof

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin &#x3b1;5&#x3b2;1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-&#x3b1;5&#x3b2;1 antibodies or antigen binding portions thereof described herein.

Alpha5-beta1 antibodies and their uses

The present invention provides isolated monoclonal antibodies that bind to CTLA-4 and that are capable of increasing the response of T cells to antigenic stimulation in vivo yet the antibodies do not substantially block the binding of CTLA-4 to B7 ligands (e.g., B7-1 and B7-2) in vitro. Thus, the antibodies of the invention demonstrate that is it possible to separate the immunostimulatory function of anti-CTLA-4 antibodies from their ability to block the binding of B7 ligands. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for increasing the response of T cells to antigenic stimulation using the antibodies of the invention, including methods for treating cancer using the antibodies of the invention.

Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof

Growing community of inventors

San Jose, CA, United States of America

Kristopher Toy